
Opinion|Videos|January 27, 2025
Supporting Mothers With Postpartum Depression and Promoting Culturally Sensitive Care
Panelists discuss how faster-acting treatments like zuranolone might improve patient outcomes and quality of life, the initial signs to monitor for assessing effectiveness, barriers to accessing such therapies in underserved populations and strategies to increase accessibility, approaches to ensuring safety while addressing distress in patients with intrusive thoughts, effective strategies for managing sleep issues in postpartum depression (PPD), advice for the psychiatry community when treating PPD, and how to tailor advice for clinicians working with underserved populations.
Advertisement
Episodes in this series

Advertisement
Related to this article

Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.

Antipsychotic levels clarify adherence, guide dose escalation up to a point of futility, and offer more than pharmacogenetic testing, says Jonathan Meyer, MD.

Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.

How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.

Male athletes with anorexia often go unnoticed as “discipline”; learn red flags, sport-specific risks, health consequences, and treatment steps for earlier diagnosis.

Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.

Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
Advertisement
Advertisement
Trending on Psychiatric Times
1
How Best to Manage Treatment-Resistant Depression
2
Choosing an Antidepressant: Art, Science, and Knowing Your Patient
3
Antipsychotic Plasma Levels in Schizophrenia: Detecting Nonadherence and Guiding Dose Decisions
4
Podcast: Using Antipsychotic Plasma Levels to Guide Schizophrenia Treatment With Jonathan M. Meyer, MD
5


